ECTS2014 Poster Presentations Bone development/growth and fracture repair (55 abstracts)
Comparison of a novel bone device OSTEOGROW with commercial bone devices in regard of a local inflammatory reaction
Lovorka Grgurevic 1 , Igor Erjavec 1 , Jelena Brkljacic 1 , Martina Pauk 1 , Mladenka Jurin 2 , Irena Popek 2 , Morana Jankolija 2 , Donatella Verbanac 3 , Mihaela Peric 3 , Hermann Oppermann 2 & Slobodan Vukicevic 1
1Laboratory for Mineralized Tissues, Center for Translational and Clinical Research, University of Zagreb School of Medicine, Zagreb, Croatia; 2Genera Research, Rakov Potok, Croatia; 3Department for Intercellular Communication, Center for Translational and Clinical Research, University of Zagreb School of Medicine, Zagreb, Croatia.
BMP6 is a member of the TGFβ superfamily with a high potential to induce new bone formation. Recently, we discovered that blood coagulum from the patient’s own blood (WBCD) modified with calcium salts serves as an appropriate autologous carrier for BMPs (OSTEOGROW device). Preclinical experiments indicate that BMP6 is efficacious when used in a significantly lower amounts than BMP2 and BMP7. Besides testing its osteogenic activity, we also tested the influence of the novel OSTEOGROW device on inflammatory reaction in the surrounding tissue, as compared to commercially available bone devices. Male CD1 mice and female Sprague–Dawley rats were allocated into five experimental groups as follows: negative control (vehicle); treatment groups (0.6, 3 and 6 μg rhBMP6 Genera Research); and rat groups were: negative control (vehicle); treatment groups (2, 11, and 22 μg rhBMP6 Genera Research). WBCD was prepared from animals’ autologous blood according to the standard protocol and the device was implanted deep into the thoracic sc pockets. Implants were removed on day 14 for μCT and histological analysis. The implantation of the WBCD device prepared with rhBMP6 protein (Genera Research) resulted in the equivalent formation of ectopic bone as assessed by μCT. High and medium doses induced noticeable ectopic bone formation. New bone in the ectopic bone fragment was dominantly located at the periphery of the implants with the signs of new trabecular bone formation in the middle of the implant. Observation of the inflammatory reaction in the surrounding tissue in rats and mice with implanted WBCD devices revealed no inflammation at the implantation site. The Helistat collagen sponge implant used with BMP2 and BMP7 commercial bone devices triggers a pronounced inflammatory response. The OSTEOGROW device is non-immunogenic and non-inflammatory, and therefore safe device to use in future applications.
Article tools
My recent searches
My recently viewed abstracts
Authors
Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more